Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonodynamic Therapy With SONALA-001 or 5-ALA HCl and MRgFUS in Progressive or Recurrent Glioblastoma
NCT07076472Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by Mayo Clinic. Primary endpoints: Incidence of adverse events at 30 days, Incidence of grade 3 or higher non-hematologic AEs at 30 days and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07076472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076472.